Drug · CHEMBL727
THIOGUANINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. THIOGUANINE. Drugs and targets, record CHEMBL727. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL727
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- NSC-752, NSC-76504, Thioguanine anhydrous, Thioguanine hemihydrate, Thioguanine, anhydrous, Tioguanina, Tioguanine, Tioguanine hemihydrate
- ChEMBL
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | https://conductscience.org/library/genes/3614 |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | INHIBITOR | https://conductscience.org/library/genes/3615 |
Source ChEMBL
Diseases24
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute lymphoblastic leukemia | Approval | TTD | 46 | 45 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| acute myeloid leukemia | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| lymphoblastic lymphoma | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0000873 |
| myelodysplastic syndrome | Phase 3 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0018881 |
| T-cell acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0004963 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| B-cell acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004947 |
| Crohn disease | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005011 |
| Hodgkins lymphoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004952 |
| Langerhans cell histiocytosis | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0018310 |
1 to 10 of 24Source Open Targets
See all 24 diseasesTrials69
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | Phase 3 | 9,350 | 2020-06-23 | thioguanine | Its name | ClinicalTrials.gov |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | Phase 3 | 5,949 | 2024-03-12 | thioguanine | Its name | ClinicalTrials.gov |
| NCT00103285 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Phase 3 | 5,377 | 2018-07-11 | thioguanine | Its name | ClinicalTrials.gov |
| NCT00075725 | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | Phase 3 | 3,154 | 2015-08-06 | thioguanine | Its name | ClinicalTrials.gov |
| NCT00408005 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | Phase 3 | 1,895 | 2019-06-20 | thioguanine | Its name | ClinicalTrials.gov |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | Phase 3 | 669 | 2022-12-06 | thioguanine | Its name | ClinicalTrials.gov |
| NCT00549848 | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Phase 3 | 600 | 2022-02-10 | thioguanine | Its name | ClinicalTrials.gov |
| NCT00004228 | Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma | Phase 3 | 393 | 2013-12-05 | thioguanine | Its name | ClinicalTrials.gov |
| NCT00558519 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Phase 2 | 318 | 2020-01-31 | thioguanine | Its name | ClinicalTrials.gov |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | Phase 3 | 280 | 2025-06-13 | thioguanine | Its name | ClinicalTrials.gov |
1 to 10 of 69
See all 69 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29) | 4,378 of 4,609 | 258 of 362 | 4,971 | NCT00103285 | Trial comparisons |
| KMT2A-Rearranged vs KMT2A-Germline: deaths from any cause | 17 of 56 | 1 of 22 | 78 | NCT02828358 | Trial comparisons |
| KMT2A-Rearranged vs KMT2A-Germline: serious adverse events | 34 of 56 | 1 of 22 | 78 | NCT02828358 | Trial comparisons |
Papers from its trials167
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL727
GET https://conductscience.org/api/drugs/v1/CHEMBL727/diseases?page=2